Valuation Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 11/12/2024			5-day change	1st Jan Change
184,200.00 ^KRW	+1.15%		+0.66%	-8.59%

12-10	South Korean Shares Rebound on Market Stabilization Optimism; Celltrion Gains 4% on Asthma Drug's Canada Approval	MT
12-10	Health Canada Approves Celltrion's Asthma Biosimilar Omlyclo; Shares Rise 3%	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	24,175,552	48,989,351	27,592,583	23,000,359	27,970,378	37,973,248	-	-
Change	-	102.64%	-43.68%	-16.64%	21.61%	35.76%	-	-
Enterprise Value (EV) ¹	24,047	49,090	27,117	23,236	29,280	39,061	38,868	38,342
Change	-	104.14%	-44.76%	-14.31%	26.01%	33.41%	-0.49%	-1.35%
P/E ratio	77.7x	94.4x	47.2x	41.6x	53.7x	87.2x	32.6x	23.5x
PBR	8.27x	14.4x	6.87x	5.34x	2.46x	2.26x	2.13x	1.96x
PEG	-	1.4x	3.8x	-9.54x	-20.3x	-2x	0x	0.6x
Capitalization / Revenue	21.4x	26.5x	14.6x	10.1x	12.9x	10.9x	8.61x	7.1x
EV / Revenue	21.3x	26.5x	14.3x	10.2x	13.5x	11.2x	8.82x	7.17x
EV / EBITDA	44.8x	55.1x	27.9x	26.6x	32.6x	40.2x	20.9x	15.7x
EV / EBIT	63.6x	68.9x	36x	35.9x	44.9x	67.6x	25.6x	18.2x
EV / FCF	63.3x	186x	46x	-211x	89.5x	42.1x	33.4x	28.5x
FCF Yield	1.58%	0.54%	2.17%	-0.47%	1.12%	2.38%	2.99%	3.51%
Dividend per Share ³	-	-	721.2	-	500	500	505.6	609.3
Rate of return	-	-	0.38%	-	0.25%	0.27%	0.27%	0.33%
EPS ³	2,153	3,586	4,031	3,855	3,753	2,113	5,652	7,847
Distribution rate	-	-	17.9%	-	13.3%	23.7%	8.94%	7.76%
Net sales ¹	1,128	1,849	1,891	2,284	2,176	3,485	4,408	5,347
EBITDA ¹	537.3	891.4	972.1	873.6	897.2	972.1	1,856	2,450
EBIT ¹	378.1	712.1	753.9	647.2	651.5	577.5	1,516	2,105
Net income ¹	297.6	511.3	575.1	533.2	535.6	461.5	1,213	1,644
Net Debt ¹	-128.5	100.4	-475.5	235.5	1,310	1,088	895.1	369.1
Reference price ³	167,280.34	338,423.83	190,384.62	160,500.00	201,500.00	184,200.00	184,200.00	184,200.00
Nbr of stocks (in thousands)	144,521	144,757	144,931	143,304	138,811	206,152	-	-
Announcement Date	19/02/20	22/02/21	16/02/22	03/03/23	29/02/24	-	-	-

¹KRW in Million²KRW in Billions³KRW

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
CELLTRION, INC.	86.18x	11.08x	39.74x	+0.27%	26.23B
LONZA GROUP AG	44.41x	6.18x	21.93x	+0.86%	42.84B
IQVIA HOLDINGS INC.	27.52x	3.19x	13.31x	-.--%	36.88B
ICON PUBLIC LIMITED COMPANY	24.82x	2.47x	11.81x	-.--%	17.83B
UNITED THERAPEUTICS CORPORATION	14.78x	4.86x	9.42x	-.--%	16.17B
MODERNA, INC.	-4.43x	2.38x	-2.2x	-.--%	15.97B
BIO-TECHNE CORPORATION	64.19x	9.94x	28.3x	+0.41%	12.25B
MEDPACE HOLDINGS, INC.	28.58x	4.79x	21.95x	-.--%	10.6B
QIAGEN N.V.	62.28x	5.3x	14.29x	-.--%	10.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	33.79x	3.02x	12.2x	-.--%	10.08B
Average	38.21x	5.32x	17.08x	+0.15%	19.91B
Weighted average by Cap.	39.46x	5.48x	18.33x	+0.25%